Seoul, South Korea

Mi Young Choi

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Fnct Biotech, Inc. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mi Young Choi: Innovator in Pulmonary Fibrosis Treatment

Introduction

Mi Young Choi is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of medical research, particularly in the treatment of pulmonary fibrosis. Her innovative approach has led to the development of a unique patent that addresses this serious health condition.

Latest Patents

Mi Young Choi holds a patent for the "Use of G-CSF antibody for treatment of pulmonary fibrosis." This patent discloses a new use of M-CSF or G-CSF as a useful marker for the diagnosis or treatment of pulmonary fibrosis. The invention includes a composition containing M-CSF inhibitor and/or G-CSF inhibitor as active ingredients, which are suitable for preventing or treating pulmonary fibrosis. The composition has been shown to significantly inhibit myofibroblast hyperplasia or pulmonary fibrosis in pulmonary cells.

Career Highlights

Mi Young Choi is currently associated with Fnct Biotech, Inc., where she continues her research and development efforts. Her work is pivotal in advancing therapeutic options for patients suffering from pulmonary fibrosis.

Collaborations

Some of her notable coworkers include Hae June Lee and Jae Kyung Myung, who contribute to the collaborative efforts in their research projects.

Conclusion

Mi Young Choi's innovative work in the treatment of pulmonary fibrosis showcases her dedication to improving patient outcomes through scientific research. Her patent reflects a significant advancement in medical treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…